impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Letter

 

Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis

1, 2, 3

 

  1. INSERM CIC-1431, Clinical Investigation Center in Biotherapy; Fédération Hospital-Universitaire INCREASE; Dept. of Rheumatology, University Hospital of Besançon; Univ. of Bourgogne Franche-Comté, Dept. of Therapeutics and EPILAB EA4266, Besançon, France.
  2. Department of Nephrology, Hôpital Nord Franche-Comté, Trevenans, France.
  3. Department of Rheumatology, Hôpital Nord Franche-Comté, Trevenans, France.

CER11613
2019 Vol.37, N°2
PI 0344, PF 0345
Letter

Free to view
(click on article PDF icon to read the article)

PMID: 30873944 [PubMed]

Received: 12/08/2018
Accepted : 09/10/2018
In Press: 07/03/2019
Published: 19/03/2019

Rheumatology Article